Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
São Paulo Gov. Joao Doria holds a box of the CoronaVac vaccine during a press conference. Photo: Alexandre Schneider via Getty Images
A coronavirus vaccine produced by Chinese company Sinovac is 78% effective, Brazil officials announced Thursday.
Why it matters: Regulators in other countries are closely following the Phase 3 trials in Brazil. If the vaccine is approved for use, it could help fill a gap in access to coronavirus vaccines for many low- and middle-income countries.
Details: Brazil’s Butantan Institute, a medical research institute in São Paulo, conducted the study of the vaccine, named CoronaVac, with 12,476 volunteers.
- The vaccine prevented all participants from developing severe cases of COVID-19, officials said.
- Brazil has the third-highest number of cases in the world after the U.S. and India, data from Johns Hopkins University shows.
- The Butantan Institute said it will request authorization for emergency use of the vaccine in Brazil, per the Wall Street Journal.
- Other countries, including Turkey and Indonesia, are also testing the CoronaVac vaccine.
The big picture: Sinovac has already sold over 300 million doses, primarily to low- and middle-income countries, per New York Times.
- Sinovac says it will be able to produce 600 million doses this year.
Health regulators in China said late last month that they have approved the country's first homegrown COVID-19 vaccine, developed by the state-owned pharmaceutical company Sinopharm, for general use.
- Sinopharm said that preliminary data have shown the vaccine to be 79.3% effective, though experts have said important data is missing.
Go deeper...The challenge of 2021: Vaccinating the world